Evidence map›Paper›PMID 25403664›Full record

ArticleAntimicrobial agents and chemotherapy2015

Inappropriate continued empirical vancomycin use in a hospital with a high prevalence of methicillin-resistant Staphylococcus aureus.

Nak-Hyun Kim, Hei Lim Koo, Pyoeng Gyun Choe, Pyeong Gyun Choe, Shinhye Cheon, Moonsuk Kim, Moon Suk Kim, Myung Jin Lee, Younghee Jung, Young Hee Jung and 9 more

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05975671 (Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05975671 narecruitingnot on this mapstarted 2023, after this paper: background citation

Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis (REVAMP-Sepsis)

TypeinterventionalSponsorChildren's Hospital of PhiladelphiaRan2023 to 2026Enrolled52,500ConditionsSepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced NephropathyArmsMultifaceted de-implementation strategy to reduce vancomycin overuse
3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Appropriateness of intravenous vancomycin prescribing in a Canadian acute care hospital.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Perioperative antibiotic use in vagus nerve stimulator implantation: a clinical series.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2017
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Nak-Hyun KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Hei Lim KooInfection Control Service, Seoul National University Hospital, Seoul, Republic of Korea.
Pyoeng Gyun Choe
Pyeong Gyun ChoeDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea Infection Control Service, Seoul National University Hospital, Seoul, Republic of Korea.
Shinhye CheonDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Moonsuk Kim
Moon Suk KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Myung Jin LeeDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Younghee Jung
Young Hee JungDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Wan Beom ParkDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kyoung-Ho SongDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Eu Suk KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Ji Hwan BangDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Hong Bin KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Sang Won ParkDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Nam Joong KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea Infection Control Service, Seoul National University Hospital, Seoul, Republic of Korea molder@unitel.co.kr.
Myoung-don OhDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Eui Chong KimDepartment of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vancomycin is frequently inappropriately prescribed, especially as empirical treatment. The aim of this study was to evaluate (i) the amount of inappropriate continued empirical vancomycin use as a proportion of total vancomycin use and (ii) the risk factors associated with inappropriate continued empirical vancomycin use. We reviewed the medical records of adult patients who had been prescribed at least one dose of parenterally administered vancomycin between January and June 2012, in a single tertiary care hospital. When empirically prescribed vancomycin treatment was continued after 96 h without documentation of beta-lactam-resistant Gram-positive microorganisms in clinical specimens with significance, the continuation was considered inappropriate, and the amount used thereafter was considered inappropriately used. We identified risk factors associated with inappropriate continued empirical vancomycin use by multiple logistic regression. During the study period, the amount of parenterally administered vancomycin prescribed was 34.2 defined daily doses (DDDs)/1,000 patient-days (1,084 prescriptions for 971 patients). The amount of inappropriate continued empirical vancomycin use was 8.5 DDDs/1,000 patient-days, which represented 24.9% of the total parenterally administered vancomycin used (8.5/34.2 DDDs/1,000 patient-days). By multivariate analyses, inappropriate continued empirical vancomycin use was independently associated with the absence of any documented etiological organism (adjusted odds ratio [aOR], 1.60 [95% confidence interval {CI}, 1.06 to 2.41]) and suspected central nervous system (CNS) infections (aHR, 2.33 [95% CI, 1.20 to 4.50]). Higher Charlson's comorbidity index scores were inversely associated with inappropriate continued empirical vancomycin use (aHR, 0.90 [95% CI, 0.85 to 0.97]). Inappropriate continued empirical vancomycin use represented 24.9% of the total amount of vancomycin prescribed, which indicates room for improvement.

Indexed as

Anti-Bacterial AgentsFemaleHumansLogistic ModelsMaleMethicillin-Resistant Staphylococcus aureusPrevalenceRetrospective StudiesRisk FactorsVancomycinAnti-Bacterial AgentsVancomycin

Identifiers

PMID25403664
PMCPMC4335878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.